Joseph Garasic, MD
Interventional Cardiology · Boston, MANPI 1154303808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $149,336 of the $151,858 with a category attached, or 98.3%. 9 manufacturers reported payments, led by AbbVie at 51.2% of the total. Among interventional cardiology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $1234.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$78K
- Abbott$29K
- Recor Medical Inc$11K
- Siemens Medical Solutions USA, Inc.$8K
- Sanofi US Services Inc.$7K
- Boehringer Ingelheim International GmbH$7K
- plus $12K from 3 others
Across 335 payments — averaging $531.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$83K
- Takeda Pharmaceuticals U.S.A., Inc.$50K
- Recor Medical Inc$30K
- Beckman Coulter, Inc.$7K
- AbbVie$4K
- Novo Nordisk AS$3K
Across 7 payments — averaging $54.29 each. An ownership or investment interest held by the physician or an immediate family member.
- Verge Medical, Inc.$380
What the payments were for
- Consulting fees$149,33698%
- Speaking & faculty fees$1,0001%
- Travel & lodging$1,4961%
- Food & beverage$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $77,788 |
| Abbott | 56 | $28,725 |
| Recor Medical Inc | 10 | $11,497 |
| Siemens Medical Solutions USA, Inc. | 7 | $8,100 |
| Sanofi US Services Inc. | 6 | $6,833 |
| Boehringer Ingelheim International GmbH | 5 | $6,825 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $6,800 |
| Pfizer | 2 | $3,240 |
| Boehringer Ingelheim | 2 | $2,050 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$14,850
- Paradise Ultrasound Renal Denervation System$11,361
- Tendyne Mitral Valve System$5,030
- LITFULO$2,625
- TENDYNE$1,625
- Rinvoq$1,100
- Absorb GT1$1,000
- XIENCE SIERRA$325
- Mitra Clip system$300
How this compares
$151,858 in reported general payments places this provider in the 90th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
- Hector Tamez AguilarBoston$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.